Cancer and autoimmune diseases are the two devastating conditions that together constitute a leading health problem worldwide. The rising burden of these disorders in the developing world demands a multifaceted approach to address the challenges it poses.
Immunotherapy is an umbrella term used to describe therapies that directly target the immune system to combat disease. For many years, immunotherapy has mainly been used to diminish immune responses in diseases traditionally classified as immunemediated, such as autoimmunity and allergy, and to promote tolerance to transplanted tissues and organs.
By targeting inhibitory checkpoint molecules, with resultant
reinvigoration of antitumor immunity, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment .
Specific differences in cancer risk have been observed between systemic lupus erythematosus patients and the general population. Although meta-analyses have estimated cancer incidence in systemic lupus erythematosus patients, results have been inconclusive.
Our understanding of the pivotal role the immune system plays in the pathogenesis of many diseases is continually expanding. Huge advances have been made in elucidating the complex immunologic
background of several diseases, including Alzheimer’s disease, Parkinson’s disease, and asthma [1,2].
Autoantibody specificity and disease subtype are biologically meaningful filters that may inform cancer risk stratification in patients with scleroderma. Future research testing the value of targeted cancer screening strategies in patients with scleroderma is needed. Recent studies that demonstrate autoantibodies are powerful tools to interrogate molecular events linking cancer and the development of autoimmunity in scleroderma.
improvement of clinical manifestations
Cancer development in Korean patients with
ANCA-associated vasculitis: a single centre study
Myositis as an adverse event of immune checkpoint
blockade for cancer therapy; Myositis as a complication
of immune checkpoint blockade
Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis